[1]
Ossenkoppele, G.J.; Janssen, J.J.; van de Loosdrecht, A.A. Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. Haematologica, 2016, 101(1), 20-25.
[2]
Leufven, E.; Bruserud, Ø. Immunosuppression and immunotargeted therapy in acute myeloid leukemia – the potential use of checkpoint inhibitors in combination with other treatments. Curr. Med. Chem., 2019, 26(28), 5244-5261.
[3]
Azrakhsh, N.A.; Mensah-Glanowska, P.; Sand, K.; Kittang, A.O. Targeting immune signaling pathways in clonal hematopoiesis. Curr. Med. Chem., 2019, 26(28), 5262-5277.
[4]
Singh, A.; Myklebust, N.N.; Furevik, S.M.V.; Haugse, R.; Herfindal, L. Immunoliposomes in acute myeloid leukaemia therapy. An overview of possible targets and obstacles. Curr. Med. Chem., 2019, 26(28), 5278-5292.